RVMD stock forecast, quote, news & analysis
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers... Show more
Revolution Medicines (RVMD) Stock Analysis: Rasonque Launch Meets a $41 Billion Valuation Test
Key Takeaways
- RVMD shares declined about 6.8% over the last 30 days, from a close of $205.26 on September 30 to $191.31 on October 30, reflecting a period of consolidation after a strong first half.
- The pullback follows the U.S. FDA approval of Rasonque (daraxonrasib) in August 2026 and a positive European Medicines Agency committee recommendation in October, rather than any deterioration in the company's fundamentals.
- Revolution Medicines now carries a market capitalization of roughly $41 billion and approximately $3.94 billion in cash, cash equivalents, and marketable securities as of its most recent report.
- Analyst sentiment remains broadly constructive, with a "Strong Buy" consensus and an average price target near $258.84, well above the recent trading range.
- October FDA review documents raised investor questions about response rates across KRAS mutation subtypes, contributing to the stock's near-term weakness.
- Explore more detailed metrics on Price Targets, Earnings, and Forecast pages for additional context on this ticker.
- For AI-driven trading signals across the market, explore Trending AI Robots.
Current Market Snapshot
Revolution Medicines (NASDAQ: RVMD) has transitioned from a clinical-stage biotech into a commercial-stage precision oncology company following the late-August 2026 FDA approval of Rasonque for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The stock closed at $191.31 on October 30, 2026, down roughly 6.8% from its September 30 close of $205.26. Shares have pulled back from a 52-week high of $224.31 but remain far above the 52-week low of $56.66, underscoring the magnitude of the rally that followed positive Phase 3 data and regulatory progress. With a market value near $41 billion and a beta around 1.40, the stock carries above-market volatility typical of recently commercialized biotechs.
Revolution Medicines (RVMD) Business Overview and Competitive Position
Revolution Medicines develops RAS(ON) inhibitors, a novel class of oral, tri-complex small molecules designed to block cancer-driving RAS mutations. Its lead therapy, Rasonque (daraxonrasib), is the first approved targeted treatment in this new drug class. In the pivotal Phase 3 RASolute 302 study, Rasonque delivered a median overall survival of 13.2 months versus 6.7 months for standard chemotherapy in previously treated metastatic pancreatic cancer. The company's broader pipeline includes zoldonrasib (a G12D-selective inhibitor), elironrasib (G12C-selective), and additional mutant-selective candidates across lung, pancreatic, and colorectal cancers. This multi-asset platform positions Revolution Medicines as a leading player in the emerging RAS-targeted oncology space, with institutional ownership above 90%.
Recent Developments Driving RVMD
Several verified catalysts shaped the stock over the last 30 days. On October 8, FDA multidisciplinary review documents for daraxonrasib prompted investor scrutiny after the agency cautioned that response-rate analyses were not powered for formal comparison across KRAS subtypes. Analysts at Stifel highlighted that the 32% overall response rate was disproportionately supported by G12V patients, while the larger G12D subgroup showed a lower rate, contributing to a sharp single-day decline.
Offsetting that pressure, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Rasonque in mid-October, and a wave of analysts reaffirmed constructive views. William Blair initiated coverage with an Outperform rating and a $226 target, while firms including Guggenheim, RBC Capital, Truist, and BofA Securities maintained Buy or Outperform ratings with price targets ranging into the mid-to-high $200s. The company also began building its own European commercial infrastructure, drew a $250 million tranche under its Royalty Pharma funding arrangement, and initiated the Phase 3 RASolute 309 trial evaluating Rasonque in combination with zoldonrasib in first-line pancreatic cancer.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of automated strategies that monitor thousands of tickers. Only the top-performing and most relevant robots appear in this section, allowing traders to compare approaches without sifting through the full catalog. Each robot differs in trading strategy, holding timeframe, and performance metrics, so investors can evaluate options suited to their own objectives and risk tolerance. The page is designed to help users identify patterns and signals that align with their trading style. Exploring the featured robots may offer a useful starting point for those interested in incorporating algorithmic signals into their market research.
2026 Outlook and What Investors Should Watch
Looking ahead, investors will focus on the commercial launch trajectory of Rasonque, including prescription uptake, payer dynamics, and realized net pricing rather than list price. The company's next earnings report, scheduled for November 4, 2026, may offer the first meaningful read on launch progress. Additional milestones include a colorectal cancer development strategy update expected in the fourth quarter, results from the Phase 3 RASolve 301 lung cancer trial anticipated in 2027, and data across four pivotal studies evaluating daraxonrasib and zoldonrasib in earlier treatment settings. Macroeconomic factors, competitive oncology developments, and execution risk in building a European sales organization also remain important variables. As with any pre-profit biotech, the path to justifying a $41 billion valuation depends heavily on sustained clinical and commercial execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RVMD's RSI Oscillator ascending out of oversold territory
The RSI Indicator for RVMD moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 17 similar instances when the indicator left oversold territory. In 15 of the 17 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 62 cases where RVMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for RVMD just turned positive on October 29, 2026. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +1.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in 243 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RVMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RVMD as a result. In 62 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
RVMD moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RVMD crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for RVMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.973) is normal, around the industry mean (3.051). P/E Ratio (-21.897) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology